Table 1—

Baseline clinical, biochemical, and drug usage characteristics of the RENAAL study Asian population

LosartanPlacebo
n117135
Clinical characteristics
 Age (years)59.7 ± 7.159.4 ± 7.5
 Men84 (71.8)87 (64.4)
 Smoking29 (24.8)23 (17.0)
 Duration of diabetes (years)15.0 ± 8.114.7 ± 8.3
 Duration of diabetes ≥5 years103 (88.0)123 (91.1)
 Duration of hypertension (years)7.9 (8.1)8.5 (8.0)
 Duration of hypertension ≥ 10 years33 (28.2)40 (29.6)
 BMI (kg/m2)25.2 ± 4.724.8 ± 4.3
 Systolic blood pressure (mmHg)152.1 ± 19.1151.5 ± 19.6
 Diastolic blood pressure (mmHg)81.9 ± 10.582.9 ± 11.1
 Mean arterial pressure (mmHg)105.3 ± 10.8104.6 (11.9)
 Pulse rate (bpm)76.3 (10.8)75.2 (9.6)
Medical history
 Angina pectoris9 (7.7)13 (9.6)
 Myocardial infarction5 (4.3)8 (5.9)
 Amputation3 (2.6)5 (3.7)
 Retinopathy87 (74.4)90 (66.7)
 Laser therapy25 (21.4)26 (19.3)
Laboratory values
 Urinary albumin-to-creatinine ratio (mg/g)*3.1 ± 0.53.1 ± 0.4
 Calculated glomerular filtration rate (ml/min)37.7 ± 9.837.5 ± 11.6
 Serum creatinine (mg/dl)1.9 ± 0.41.9 ± 0.5
 Serum albumin (g/dl)3.8 ± 0.53.8 ± 0.4
 Total cholesterol (mg/dl)228.8 ± 54.7227.3 ± 48.2
 LDL cholesterol (mg/dl)144.2 ± 49.3144.6 ± 46.8
 HDL cholesterol (mg/dl)45.7 ± 16.346.9 ± 17.4
 Triglyceride (mg/dl)208.1 ± 200.6207.1 ± 161.1
 Serum uric acid (mg/dl)6.63 ± 1.46.9 ± 1.8
 Hb (%)12.3 ± 2.112.1 ± 2.0
 GHb (%)8.3 ± 1.58.0 ± 1.4
 White blood cell count × 106/cc97.5 ± 1.77.1 ± 1.7
Pattern of drug usage
 Dihydropyridine calcium channel blockers84 (71.8)101 (74.8)
 Nondihydropyridine calcium channel blockers12 (10.3)10 (7.4)
 Diuretics43 (36.8)44 (32.6)
 β-Blockers20 (17.1)19 (14.1)
 ACE inhibitors/AII antagonists70 (59.8)69 (51.1)
 α-Blockers23 (19.7)26 (19.3)
 Insulin64 (54.7)65 (48.1)
  • Data are means ± SE or n (%).

  • *

    * Log transformed.